Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Carboplatin 6 Specimen Handling 5 Rituximab 5 amivantamab 4 Prednisone 4 olaparib 3 lazertinib 3 acalabrutinib 3 X-Rays 3 Pemetrexed 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Dexamethasone 3 Cyclophosphamide 3 Ado-Trastuzumab Emtansine 3 Abiraterone Acetate 3 trastuzumab deruxtecan 2 talquetamab 2 pertuzumab 2 pembrolizumab 2 osimertinib 2 niraparib 2 ipatasertib 2 erdafitinib 2 entrectinib 2 durvalumab 2 daratumumab 2 belzutifan 2 atezolizumab 2 apalutamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × polatuzumab vedotin × 30 days × Clear all

NCT03274492 2026-05-08

POLARIX

Hoffmann-La Roche

Phase 3 Completed

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡